{
    "organizations": [],
    "uuid": "3ecac382c2dea81b4dad711e1333292c2a0889d3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-crispr-therapeutics-reports-q1-los/brief-crispr-therapeutics-reports-q1-loss-per-share-0-62-idUSASC0A0GK",
    "ord_in_thread": 0,
    "title": "BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8, 2018 / 12:20 PM / Updated 18 minutes ago BRIEF-Crispr Therapeutics Reports Q1 Loss Per Share $0.62 Reuters Staff\nMay 8 (Reuters) - CRISPR Therapeutics AG:\n* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* CRISPR THERAPEUTICS AG - ON TRACK TO BEGIN CTX001 CLINICAL STUDY IN HEMOGLOBINOPATHIES IN 2018\n* CRISPR THERAPEUTICS AG - ON TRACK TO FILE IND IN 2018 FOR CTX101, ALLOGENEIC CRISPR-BASED CAR-T TARGETED TOWARD CD19+ MALIGNANCIES\n* CRISPR THERAPEUTICS AG - TOTAL COLLABORATION REVENUES WERE $1.4 MILLION FOR Q1 OF 2018 COMPARED TO $2.7 MILLION FOR Q1 OF 2017\n* CRISPR THERAPEUTICS AG - QTRLY LOSS PER SHARE $0.62\n* CRISPR THERAPEUTICS AG - HAS $341.8 MILLION IN CASH AS OF MARCH 31, 2018 Source text for Eikon: Further company coverage:",
    "published": "2018-05-08T15:19:00.000+03:00",
    "crawled": "2018-05-08T15:40:01.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "report",
        "q1",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "may",
        "reuters",
        "crispr",
        "therapeutic",
        "ag",
        "crispr",
        "therapeutic",
        "provides",
        "business",
        "update",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "crispr",
        "therapeutic",
        "ag",
        "track",
        "begin",
        "ctx001",
        "clinical",
        "study",
        "hemoglobinopathy",
        "crispr",
        "therapeutic",
        "ag",
        "track",
        "file",
        "ind",
        "ctx101",
        "allogeneic",
        "targeted",
        "toward",
        "malignancy",
        "crispr",
        "therapeutic",
        "ag",
        "total",
        "collaboration",
        "revenue",
        "million",
        "q1",
        "compared",
        "million",
        "q1",
        "crispr",
        "therapeutic",
        "ag",
        "qtrly",
        "loss",
        "per",
        "share",
        "crispr",
        "therapeutic",
        "ag",
        "million",
        "cash",
        "march",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}